Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2023-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2023
2023-05-15 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 15, 2023, reporting the company's financial results for the quarter ended March 31, 2023. It includes a press release announcing quarterly financial results and a corporate update. The document explicitly states it is a Current Report on Form 8-K and includes a press release as an exhibit. The content corresponds to an initial announcement of quarterly financial results, which aligns with the definition of an Earnings Release (ER). The document length is 3738 characters, which is relatively short but contains the actual announcement of quarterly results, not just a notice or link to a report. Therefore, it is classified as an Earnings Release (ER).
2023-05-15 English
ARS
Annual Report
2023-04-20 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement related to shareholder voting matters for an upcoming annual meeting. It includes information about voting on director elections and ratification of the independent auditor. The document is titled 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934' and is identified as 'Definitive Additional Materials.' It is not the full proxy statement itself but additional materials related to the proxy solicitation. The content focuses on voting instructions and meeting details rather than detailed governance rules or compensation information. Given the nature of the document as proxy solicitation materials, the appropriate classification is 'Proxy Solicitation & Information Statement (PSI).','filing_type_code':'PSI','confidence_score':0.95} } The document is a Schedule 14A proxy statement with voting information for the annual meeting, so it fits best under Proxy Solicitation & Information Statement (PSI). The confidence is high because the document explicitly states it is a proxy statement and contains voting proposals. The document length is short and it is not a full annual report or management report. The classification is PSI with confidence 0.95. The document is not a DEF 14A remuneration report because it does not detail compensation. It is not a Regulatory Filing (RNS) because it is a formal proxy solicitation document. It is not an AGM Information (AGM-R) because it is not meeting presentation materials. It is not a Report Publication Announcement (RPA) because it is not announcing a report release. Therefore, PSI is the best fit. The confidence is 0.95 due to clear identification and content. Final classification: PSI, confidence 0.95. The reasoning and classification are provided above. This completes the classification. The output is in the required JSON format. No other categories fit better. End of reasoning. The final answer is below.
2023-04-20 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-20 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is the resignation of a board member, Jay T. Backstrom, from the Board of Directors effective June 9, 2023. The document specifically addresses a change in the company's board of directors. There is no financial data or report attached, and the document is not an earnings release, annual report, or any other financial report. The primary focus is on management/board changes, which fits the Board/Management Information category (MANG). The document length is 3167 characters, which is short and consistent with a management change announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2023-04-19 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.